文章核心观点 - 公司宣布启动针对口腔扁平苔藓(OLP)的LP-310 II期临床试验,并已完成首批患者入组 [1][2][3] - LP-310是公司的专有脂质体他克莫司口腔漱洗剂,旨在解决OLP的潜在病因,为这一严重缺乏有效治疗的疾病提供新的治疗方案 [4][5] - 该临床试验预计于2025年中期完成,并于2024年底公布首批数据 [4] - OLP是一种严重且令人衰弱的疾病,目前治疗选择有限,突出了像LP-310这样创新疗法的重要性 [7] 公司概况 - 公司是一家处于临床阶段的生物技术公司,专注于开发通过改良现有通用药物而获得的新药物 [8] - 公司于2022年12月完成首次公开募股 [8] 行业概况 - OLP是一种严重的慢性炎症性疾病,影响全球数百万人,目前缺乏获批的治疗方法 [7]

Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH, May 31, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the successful completion of its first Site Initiation Visit (SIV) for the Phase 2a trial evaluating LP-310 in the treatment of Oral ...

Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Abstract highlighting new preclinical data from LP-50 in non-muscle invasive bladder cancer PITTSBURGH, Pa., May 29, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces an abstract publication at the 2024 American Society of Clinical O ...

Company to initiate Phase 2b clinical trial in lead asset, LP-10 in 2H 2024 Pittsburgh, PA, May 21, 2024 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration ("FDA") Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately 36 pati ...

PITTSBURGH, May 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company, announced today the receipt of U.S. Food & Drug Administration ("FDA") Type-C meeting guidance regarding the LP-10 (liposomal tacrolimus) clinical program. Lipella expects to initiate a Phase 2b clinical trial evaluating LP-10 as a treatment for hemorrhagic cystitis in approximately 36 patients in the second half of 2024. The FDA provided preliminary a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 20-2388040 (State or other ...

Lipella Pharmaceuticals Inc. - Lipella Pharmaceuticals Inc.宣布扩大其科学顾问委员会，增加了肿瘤学专业知识[1] - 新委员会成员包括Jason Hafron博士和Pradeep Tyagi博士，两位专家在癌症治疗的临床和转化研究方面具有互补的专业知识[2] - Lipella是一家临床阶段的生物技术公司，专注于开发新药物，通过重新制剂化现有通用药物中的活性成分，并优化这些重新制剂化以应用于新的领域[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-41575 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) | Delaware | 20-2388040 | | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41575 Lipella Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) Delaware 20-2388040 (State or other ...